IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 320 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,058,657 | +28.9% | 23,339 | +16.6% | 0.01% | +25.0% |
| Q2 2023 | $821,092 | +14.8% | 20,012 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $715,229 | +1.3% | 20,012 | +7.0% | 0.00% | -25.0% |
| Q4 2022 | $706,186 | -4.6% | 18,697 | +11.7% | 0.00% | 0.0% |
| Q3 2022 | $740,000 | +19.5% | 16,734 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $619,000 | -8.4% | 16,734 | -8.3% | 0.00% | +33.3% |
| Q1 2022 | $676,000 | +0.4% | 18,248 | -17.5% | 0.00% | 0.0% |
| Q4 2021 | $673,000 | +56.5% | 22,121 | +72.6% | 0.00% | +50.0% |
| Q3 2021 | $430,000 | -15.9% | 12,817 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $511,000 | -46.4% | 12,817 | -39.6% | 0.00% | -50.0% |
| Q1 2021 | $954,000 | -20.5% | 21,221 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $1,200,000 | -28.8% | 21,221 | -40.2% | 0.01% | -41.7% |
| Q3 2020 | $1,685,000 | +43.9% | 35,510 | +78.8% | 0.01% | +20.0% |
| Q2 2020 | $1,171,000 | +8.9% | 19,865 | -12.6% | 0.01% | 0.0% |
| Q1 2020 | $1,075,000 | -17.5% | 22,730 | +5.4% | 0.01% | 0.0% |
| Q4 2019 | $1,303,000 | -1.0% | 21,564 | -1.9% | 0.01% | -9.1% |
| Q3 2019 | $1,316,000 | -14.0% | 21,974 | -7.7% | 0.01% | -15.4% |
| Q2 2019 | $1,530,000 | +18.3% | 23,801 | +49.4% | 0.01% | +8.3% |
| Q1 2019 | $1,293,000 | +35.1% | 15,926 | -10.1% | 0.01% | +20.0% |
| Q4 2018 | $957,000 | +91.4% | 17,709 | +82.7% | 0.01% | +150.0% |
| Q3 2018 | $500,000 | +32.3% | 9,695 | +6.8% | 0.00% | +33.3% |
| Q2 2018 | $378,000 | -5.5% | 9,079 | 0.0% | 0.00% | -25.0% |
| Q1 2018 | $400,000 | -14.3% | 9,079 | -2.2% | 0.00% | 0.0% |
| Q4 2017 | $467,000 | -9.0% | 9,279 | -8.4% | 0.00% | -20.0% |
| Q3 2017 | $513,000 | +106.9% | 10,125 | +107.5% | 0.01% | +150.0% |
| Q2 2017 | $248,000 | -26.4% | 4,880 | -41.8% | 0.00% | -33.3% |
| Q1 2017 | $337,000 | -54.5% | 8,385 | -45.9% | 0.00% | -62.5% |
| Q4 2016 | $741,000 | +41.7% | 15,491 | +8.6% | 0.01% | +60.0% |
| Q3 2016 | $523,000 | +40.6% | 14,261 | -10.8% | 0.01% | 0.0% |
| Q2 2016 | $372,000 | -33.6% | 15,987 | +15.7% | 0.01% | -28.6% |
| Q1 2016 | $560,000 | -34.6% | 13,816 | 0.0% | 0.01% | -36.4% |
| Q4 2015 | $856,000 | – | 13,816 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |